David Jones

List of Publications by Citations

142 papers	4,682 citations	34 h-index	66 g-index
150 ext. papers	6,674 ext. citations	6.5 avg, IF	5.76 L-index

#	Paper	IF	Citations
142	Defining imaging biomarker cut points for brain aging and Alzheimer's disease. *Alzheimer's and Dementia*, **2017**, 13, 205-216	1.2	358
141	An autoradiographic evaluation of AV-1451 Tau PET in dementia. *Acta Neuropathologica Communications*, **2016**, 4, 58	7.3	305
140	Non-stationarity in the "resting brain's" modular architecture. *PLoS ONE*, **2012**, 7, e39731	3.7	293
139	Cascading network failure across the Alzheimer's disease spectrum. *Brain*, **2016**, 139, 547-62	11.2	265
138	Longitudinal tau PET in ageing and Alzheimer's disease. *Brain*, **2018**, 141, 1517-1528	11.2	194
137	Effect of APOE 4 status on intrinsic network connectivity in cognitively normal elderly subjects. *Archives of Neurology*, **2011**, 68, 1131-6		176
136	Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity. *Neurology*, **2013**, 81, 1732-40	6.5	142
135	Widespread brain tau and its association with ageing, Braak stage and Alzheimer's dementia. *Brain*, **2018**, 141, 271-287	11.2	139
134	Disrupted thalamocortical connectivity in PSP: a resting-state fMRI, DTI, and VBM study. *Parkinsonism and Related Disorders*, **2011**, 17, 599-605	3.6	125
133	Spread of pathological tau proteins through communicating neurons in human Alzheimer's disease. *Nature Communications*, **2020**, 11, 2612	17.4	118
132	Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles With Rates of Memory Decline Among Individuals Without Dementia. *JAMA - Journal of the American Medical Association*, **2019**, 321, 2316-2325	27.4	115
131	AV-1451 tau and β-amyloid positron emission tomography imaging in dementia with Lewy bodies. *Annals of Neurology*, **2017**, 81, 58-67	9.4	115
130	Alzheimer disease. *Nature Reviews Disease Primers*, **2021**, 7, 33	51.1	114
129	Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019. *Alzheimer's and Dementia*, **2021**, 17, 696-701	1.2	107
128	Prevalence of Biologically vs Clinically Defined Alzheimer Spectrum Entities Using the National Institute on Aging-Alzheimer's Association Research Framework. *JAMA Neurology*, **2019**,	17.2	106
127	Tau, amyloid, and cascading network failure across the Alzheimer's disease spectrum. *Cortex*, **2017**, 97, 143-159	3.8	105
126	Classification and clinicoradiologic features of primary progressive aphasia (PPA) and apraxia of speech. *Cortex*, **2015**, 69, 220-36	3.8	99

125	Evaluation of Amyloid Protective Factors and Alzheimer Disease Neurodegeneration Protective Factors in Elderly Individuals. *JAMA Neurology*, **2017**, 74, 718-726	17.2	87
124	The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromes. *Brain*, **2019**, 142, 3230-3242	11.2	77
123	Resting state functional MRI in Alzheimer's Disease. *Alzheimer's Research and Therapy*, **2012**, 4, 2	9	76
122	Working memory and language network dysfunctions in logopenic aphasia: a task-free fMRI comparison with Alzheimer's dementia. *Neurobiology of Aging*, **2015**, 36, 1245-52	5.6	64
121	The neuroanatomy of pure apraxia of speech in stroke. *Brain and Language*, **2014**, 129, 43-6	2.9	62
120	Mesenchymal Stromal Cell Therapies for Neurodegenerative Diseases. *Mayo Clinic Proceedings*, **2019**, 94, 892-905	6.4	53
119	Tau-positron emission tomography correlates with neuropathology findings. *Alzheimer's and Dementia*, **2020**, 16, 561-571	1.2	52
118	Entorhinal cortex tau, amyloid-β cortical thickness and memory performance in non-demented subjects. *Brain*, **2019**, 142, 1148-1160	11.2	49
117	Imaging correlations of tau, amyloid, metabolism, and atrophy in typical and atypical Alzheimer's disease. *Alzheimer's and Dementia*, **2018**, 14, 1005-1014	1.2	47
116	[F]AV-1451 tau-PET and primary progressive aphasia. *Annals of Neurology*, **2018**, 83, 599-611	9.4	46
115	FDG-PET in tau-negative amnestic dementia resembles that of autopsy-proven hippocampal sclerosis. *Brain*, **2018**, 141, 1201-1217	11.2	46
114	New insights into atypical Alzheimer's disease in the era of biomarkers. *Lancet Neurology, The*, **2021**, 20, 222-234	24.1	45
113	[F]AV-1451 clustering of entorhinal and cortical uptake in Alzheimer's disease. *Annals of Neurology*, **2018**, 83, 248-257	9.4	42
112	Magnetic resonance elastography of frontotemporal dementia. *Journal of Magnetic Resonance Imaging*, **2016**, 43, 474-8	5.6	41
111	In vivo F-AV-1451 tau PET signal in mutation carriers varies by expected tau isoforms. *Neurology*, **2018**, 90, e947-e954	6.5	37
110	Cross-sectional associations of tau-PET signal with cognition in cognitively unimpaired adults. *Neurology*, **2019**, 93, e29-e39	6.5	36
109	Progressive dysexecutive syndrome due to Alzheimer's disease: a description of 55 cases and comparison to other phenotypes. *Brain Communications*, **2020**, 2, fcaa068	4.5	36
108	Duration and Pathologic Correlates of Lewy Body Disease. *JAMA Neurology*, **2017**, 74, 310-315	17.2	31

107	βAmyloid PET and neuropathology in dementia with Lewy bodies. *Neurology*, **2020**, 94, e282-e291	6.5	31
106	Neuroimaging correlates with neuropathologic schemes in neurodegenerative disease. *Alzheimer's and Dementia*, **2019**, 15, 927-939	1.2	30
105	Predicting Survival in Dementia With Lewy Bodies With Hippocampal Volumetry. *Movement Disorders*, **2016**, 31, 989-94	7	27
104	Default mode network disruption secondary to a lesion in the anterior thalamus. *Archives of Neurology*, **2011**, 68, 242-7		26
103	Mediodorsal nucleus and its multiple cognitive functions. *Neurology*, **2016**, 87, 2161-2168	6.5	25
102	Predicting future rates of tau accumulation on PET. *Brain*, **2020**, 143, 3136-3150	11.2	25
101	F-FDG PET-CT pattern in idiopathic normal pressure hydrocephalus. *NeuroImage: Clinical*, **2018**, 18, 897-902	5.3	24
100	Longitudinal neuroimaging biomarkers differ across Alzheimer's disease phenotypes. *Brain*, **2020**, 143, 2281-2294	11.2	23
99	Caudate nucleus as a component of networks controlling behavior. *Neurology*, **2017**, 89, 2192-2197	6.5	22
98	A robust biomarker of large-scale network failure in Alzheimer's disease. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2017**, 6, 152-161	5.2	21
97	Joint associations of βamyloidosis and cortical thickness with cognition. *Neurobiology of Aging*, **2018**, 65, 121-131	5.6	21
96	LRRK2 variation and dementia with Lewy bodies. *Parkinsonism and Related Disorders*, **2016**, 31, 98-103	3.6	21
95	Age and neurodegeneration imaging biomarkers in persons with Alzheimer disease dementia. *Neurology*, **2016**, 87, 691-8	6.5	20
94	Comparison of the Short Test of Mental Status and the Montreal Cognitive Assessment Across the Cognitive Spectrum. *Mayo Clinic Proceedings*, **2019**, 94, 1516-1523	6.4	20
93	Contributions of imprecision in PET-MRI rigid registration to imprecision in amyloid PET SUVR measurements. *Human Brain Mapping*, **2017**, 38, 3323-3336	5.9	19
92	Role of βAmyloidosis and Neurodegeneration in Subsequent Imaging Changes in Mild Cognitive Impairment. *JAMA Neurology*, **2015**, 72, 1475-83	17.2	19
91	Tau-negative amnestic dementia masquerading as Alzheimer disease dementia. *Neurology*, **2018**, 90, e940-e946	6.5	19
90	Disrupted functional connectivity in primary progressive apraxia of speech. *NeuroImage: Clinical*, **2018**, 18, 617-629	5.3	19

89	RAB39B gene mutations are not a common cause of Parkinson's disease or dementia with Lewy bodies. *Neurobiology of Aging*, **2016**, 45, 107-108	5.6	18
88	Automated detection of imaging features of disproportionately enlarged subarachnoid space hydrocephalus using machine learning methods. *NeuroImage: Clinical*, **2019**, 21, 101605	5.3	18
87	Assessment of executive function declines in presymptomatic and mildly symptomatic familial frontotemporal dementia: NIH-EXAMINER as a potential clinical trial endpoint. *Alzheimer's and Dementia*, **2020**, 16, 11-21	1.2	18
86	Individualized atrophy scores predict dementia onset in familial frontotemporal lobar degeneration. *Alzheimer's and Dementia*, **2020**, 16, 37-48	1.2	18
85	Clinical and volumetric changes with increasing functional impairment in familial frontotemporal lobar degeneration. *Alzheimer's and Dementia*, **2020**, 16, 49-59	1.2	17
84	TREM2 p.R47H substitution is not associated with dementia with Lewy bodies. *Neurology: Genetics*, **2016**, 2, e85	3.8	15
83	Regional cortical perfusion on arterial spin labeling MRI in dementia with Lewy bodies: Associations with clinical severity, glucose metabolism and tau PET. *NeuroImage: Clinical*, **2018**, 19, 939-947	5.3	15
82	Relationship Between Seizure Frequency and Functional Abnormalities in Limbic Network of Medial Temporal Lobe Epilepsy. *Frontiers in Neurology*, **2019**, 10, 488	4.1	14
81	Identification and functional characterization of novel mutations including frameshift mutation in exon 4 of CSF1R in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia. *Journal of Neurology*, **2018**, 265, 2415-2424	5.5	14
80	Evolution of neurodegeneration-imaging biomarkers from clinically normal to dementia in the Alzheimer disease spectrum. *Neurobiology of Aging*, **2016**, 46, 32-42	5.6	13
79	Rates of lobar atrophy in asymptomatic mutation carriers. *Alzheimer's and Dementia: Translational Research and Clinical Interventions*, **2019**, 5, 338-346	6	13
78	Tau and Amyloid Relationships with Resting-state Functional Connectivity in Atypical Alzheimer's Disease. *Cerebral Cortex*, **2021**, 31, 1693-1706	5.1	13
77	Associations of quantitative susceptibility mapping with Alzheimer's disease clinical and imaging markers. *NeuroImage*, **2021**, 224, 117433	7.9	13
76	Association of Initial βAmyloid Levels With Subsequent Flortaucipir Positron Emission Tomography Changes in Persons Without Cognitive Impairment. *JAMA Neurology*, **2021**, 78, 217-228	17.2	13
75	Utility of FDG-PET in diagnosis of Alzheimer-related TDP-43 proteinopathy. *Neurology*, **2020**, 95, e23-e34	6.5	11
74	Elevated medial temporal lobe and pervasive brain tau-PET signal in normal participants. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2018**, 10, 210-216	5.2	11
73	Normal Pressure Hydrocephalus. *CONTINUUM Lifelong Learning in Neurology*, **2019**, 25, 165-186	3	11
72	Language networks associated with computerized semantic indices. *NeuroImage*, **2015**, 104, 125-37	7.9	10

#	Reference		
71	Frontal lobe H MR spectroscopy in asymptomatic and symptomatic mutation carriers. *Neurology*, **2019**, 93, e758-e765	6.5	10
70	Transient Epileptic Amnesia: A Treatable Cause of Spells Associated With Persistent Cognitive Symptoms. *Frontiers in Neurology*, **2019**, 10, 939	4.1	9
69	Tracking white matter degeneration in asymptomatic and symptomatic MAPT mutation carriers. *Neurobiology of Aging*, **2019**, 83, 54-62	5.6	9
68	Trajectory of lobar atrophy in asymptomatic and symptomatic GRN mutation carriers: a longitudinal MRI study. *Neurobiology of Aging*, **2020**, 88, 42-50	5.6	9
67	Neural networks, cognition, and diabetes: what is the connection?. *Diabetes*, **2012**, 61, 1653-5	0.9	8
66	Pick's disease: clinicopathologic characterization of 21 cases. *Journal of Neurology*, **2020**, 267, 2697-2704	5.5	8
65	Nuclei-specific thalamic connectivity predicts seizure frequency in drug-resistant medial temporal lobe epilepsy. *NeuroImage: Clinical*, **2019**, 21, 101671	5.3	8
64	The influence of β-amyloid on [F]AV-1451 in semantic variant of primary progressive aphasia. *Neurology*, **2019**, 92, e710-e722	6.5	8
63	CSF1R mutation presenting as dementia with Lewy bodies. *Neurocase*, **2019**, 25, 17-20	0.8	7
62	Cortical atrophy patterns of incident MCI subtypes in the Mayo Clinic Study of Aging. *Alzheimer's and Dementia*, **2020**, 16, 1013-1022	1.2	7
61	Cerebrospinal fluid dynamics disorders: Relationship to Alzheimer biomarkers and cognition. *Neurology*, **2019**, 93, e2237-e2246	6.5	7
60	Brain MR Spectroscopy Changes Precede Frontotemporal Lobar Degeneration Phenoconversion in Mapt Mutation Carriers. *Journal of Neuroimaging*, **2019**, 29, 624-629	2.8	6
59	MRI and flortaucipir relationships in Alzheimer's phenotypes are heterogeneous. *Annals of Clinical and Translational Neurology*, **2020**, 7, 707-721	5.3	6
58	Dementia with Lewy bodies: association of Alzheimer pathology with functional connectivity networks. *Brain*, **2021**, 144, 3212-3225	11.2	6
57	FDG PET metabolic signatures distinguishing prodromal DLB and prodromal AD. *NeuroImage: Clinical*, **2021**, 31, 102754	5.3	6
56	Accelerated functional brain aging in pre-clinical familial Alzheimer's disease. *Nature Communications*, **2021**, 12, 5346	17.4	6
55	Creating three dimensional models of Alzheimer's disease. *3D Printing in Medicine*, **2017**, 3, 13	5	5
54	Linear vs volume measures of ventricle size: Relation to present and future gait and cognition. *Neurology*, **2020**, 94, e549-e556	6.5	5

53	The Longitudinal Early-onset Alzheimer's Disease Study (LEADS): Framework and methodology. *Alzheimer's and Dementia*, **2021**,	1.2	5
52	Uptake of AV-1451 in meningiomas. *Annals of Nuclear Medicine*, **2017**, 31, 736-743	2.5	4
51	Our Efforts in Understanding Normal Pressure Hydrocephalus: Learning from the 100 Most Cited Articles by Bibliometric Analysis. *World Neurosurgery*, **2020**, 137, 429-434.e13	2.1	4
50	Executive Dysfunction and the Prefrontal Cortex. *CONTINUUM Lifelong Learning in Neurology*, **2021**, 27, 1586-1601	3	4
49	Disproportionately enlarged subarachnoid-space hydrocephalus (DESH) in normal pressure hydrocephalus misinterpreted as atrophy: autopsy and radiological evidence. *Neurocase*, **2019**, 25, 151-155	0.8	3
48	F-fluorodeoxyglucose positron emission tomography in dementia with Lewy bodies. *Brain Communications*, **2020**, 2, fcaa040	4.5	3
47	Frequency of Acute and Subacute Infarcts in a Population-Based Study. *Mayo Clinic Proceedings*, **2018**, 93, 300-306	6.4	3
46	Predictors of adverse outcomes and cost after surgical management for idiopathic normal pressure hydrocephalus: Analyses from a national database. *Clinical Neurology and Neurosurgery*, **2020**, 197, 106178	2	3
45	High prevalence of cervical myelopathy in patients with idiopathic normal pressure hydrocephalus. *Clinical Neurology and Neurosurgery*, **2020**, 197, 106099	2	3
44	Focal photoparoxysmal response in the Heidenhain variant of CJD: Hidden from view!. *Neurology*, **2016**, 86, 1647-8	6.5	3
43	Amyloid PET and I-FP-CIT SPECT in Mild Cognitive Impairment at Risk for Lewy Body Dementia. *Neurology*, **2021**,	6.5	3
42	Posterior cortical atrophy phenotypic heterogeneity revealed by decoding F-FDG-PET. *Brain Communications*, **2021**, 3, fcab182	4.5	3
41	Progressive Auditory Verbal Agnosia Secondary to Alzheimer Disease. *Neurology*, **2021**, 97, 908-909	6.5	3
40	A computational model of neurodegeneration in Alzheimer's disease.. *Nature Communications*, **2022**, 13, 1643	17.4	3
39	Teaching Video NeuroImages: Foix-Chavany-Marie syndrome. *Neurology*, **2019**, 92, e2620-e2621	6.5	2
38	CSF dynamics disorders: Association of brain MRI and nuclear medicine cisternogram findings. *NeuroImage: Clinical*, **2020**, 28, 102481	5.3	2
37	Longitudinal clinical, neuropsychological, and neuroimaging characterization of a kindred with a 12-octapeptide repeat insertion in : the next generation. *Neurocase*, **2020**, 26, 211-219	0.8	2
36	Artificial Intelligence and the Practice of Neurology in 2035: The Neurology Future Forecasting Series.. *Neurology*, **2022**, 98, 238-245	6.5	2

#	Citation	IF	Cites
35	Cerebrospinal fluid dynamics and discordant amyloid biomarkers. *Neurobiology of Aging*, **2021**, 110, 27-36.	5.6	2
34	Expanded genetic insight and clinical experience of DNMT1-complex disorder. *Neurology: Genetics*, **2020**, 6, e456	3.8	2
33	Cerebral Amyloid Angiopathy Burden and Cerebral Microbleeds: Pathological Evidence for Distinct Phenotypes. *Journal of Alzheimers Disease*, **2021**, 81, 113-122	4.3	2
32	IC-03-04: Network-Based TAU Deposition Patterns are Related to Functional Network Failure Largely Via Beta-Amyloid Across The Alzheimers Spectrum **2016**, 12, P11-P12		2
31	Prevalence and Trends in Management of Idiopathic Normal Pressure Hydrocephalus in the United States: Insights from the National Inpatient Sample. *World Neurosurgery*, **2021**, 145, e38-e52	2.1	2
30	Amyloid- and tau-PET imaging in a familial prion kindred. *Neurology: Genetics*, **2018**, 4, e290	3.8	2
29	Deep learning-based brain age prediction in normal aging and dementia. *Nature Aging*, **2022**, 2, 412-424		2
28	Magnetic resonance elastography of frontotemporal dementia. *Journal of Magnetic Resonance Imaging*, **2016**, 43, spcone-spcone	5.6	1
27	Functional Connectivity in Dementia **2018**, 245-266		1
26	O3-03-05: LONGITUDINAL MRI AND NEUROPSYCHOLOGICAL CHANGES IN SYMPTOMATIC FRONTOTEMPORAL LOBAR DEGENERATION SUBJECTS WITH MUTATIONS IN MAPT, PGRN, AND C9ORF72 **2014**, 10, P213-P214		1
25	Longitudinal atrophy in prodromal dementia with Lewy bodies points to cholinergic degeneration.. *Brain Communications*, **2022**, 4, fcac013	4.5	1
24	White matter damage due to vascular, tau, and TDP-43 pathologies and its relevance to cognition.. *Acta Neuropathologica Communications*, **2022**, 10, 16	7.3	1
23	Multiple aetiologies of the progressive dysexecutive syndrome and the importance of biomarkers. *Brain Communications*, **2020**, 2, fcaa127	4.5	1
22	Patterns of neurodegeneration in dementia reflect a global functional state space		1
21	P1-247: Network-Based TAU Deposition Patterns are Related to Functional Network Failure Largely Via Beta-Amyloid Across the Alzheimers Spectrum **2016**, 12, P502-P502		1
20	The value of multimodal imaging with I-FP-CIT SPECT in differential diagnosis of dementia with Lewy bodies and Alzheimer's disease dementia. *Neurobiology of Aging*, **2021**, 99, 11-18	5.6	1
19	Underlying pathology identified after 20 years of disease course in two cases of slowly progressive frontotemporal dementia syndromes. *Neurocase*, **2021**, 27, 212-222	0.8	1
18	Cerebral Amyloid Angiopathy Pathology and Its Association With Amyloid-PET Signal. *Neurology*, **2021**, 97, e1799-e1808	6.5	1

17	Relationships between β-amyloid and tau in an elderly population: An accelerated failure time model. *NeuroImage*, **2021**, 242, 118440	7.9	1
16	Progressive dysexecutive syndrome due to Alzheimer's disease: A description of 55 cases and comparisons to other clinical AD phenotypes. *Alzheimer's and Dementia*, **2020**, 16, e040622	1.2	0
15	Mechanistic Effects of Aerobic Exercise in Alzheimer's Disease: Imaging Findings From the Pilot FIT-AD Trial. *Frontiers in Aging Neuroscience*, **2021**, 13, 703691	5.3	0
14	CSF dynamics as a predictor of cognitive progression. *NeuroImage*, **2021**, 232, 117899	7.9	0
13	Electroencephalogram (EEG) With or Without Transcranial Magnetic Stimulation (TMS) as Biomarkers for Post-stroke Recovery: A Narrative Review.. *Frontiers in Neurology*, **2022**, 13, 827866	4.1	0
12	Phenotypic subtypes of progressive dysexecutive syndrome due to Alzheimer's disease: a series of clinical cases.. *Journal of Neurology*, **2022**, 1	5.5	0
11	Dissociation of tau pathology and neuronal hypometabolism within the ATN framework of Alzheimer's disease.. *Nature Communications*, **2022**, 13, 1495	17.4	0
10	Three cases of Creutzfeldt-Jakob disease presenting with a predominant dysexecutive syndrome.. *Journal of Neurology*, **2022**, 1	5.5	0
9	Deep learning identifies brain structures that predict cognition and explain heterogeneity in cognitive aging.. *NeuroImage*, **2022**, 251, 119020	7.9	0
8	Tau polygenic risk scoring: a cost-effective aid for prognostic counseling in Alzheimer's disease.. *Acta Neuropathologica*, **2022**, 143, 571	14.3	0
7	IC-P-066: Systems fail before molecules spread: A cascading failure model of Alzheimer's disease **2015**, 11, P50-P50		
6	O5-06-04: Systems fail before molecules spread: A cascading failure model of Alzheimer's disease **2015**, 11, P329-P329		
5	POS0311 NEUROIMAGING BIOMARKERS IN INDIVIDUALS WITH AND WITHOUT RHEUMATOID ARTHRITIS: RESULTS FROM THE MAYO CLINIC STUDY OF AGING. *Annals of the Rheumatic Diseases*, **2021**, 80, 381.1-382	2.4	
4	IC-P-027: DECODING GLUCOSE METABOLISM IN ALZHEIMER'S DISEASE REVEALS MACRO-SCALE BRAIN ORGANIZATION RELATED TO DISEASE EXPRESSION **2019**, 15, P34-P35		
3	IC-P-144: PRINCIPAL AXES OF PHENOTYPIC VARIABILITY IN ALZHEIMER'S DISEASE DERIVED FROM AN FDG-PET BASED, UNSUPERVISED MACHINE LEARNING ALGORITHM **2018**, 14, P122-P123		
2	P1-387: PRINCIPAL AXES OF PHENOTYPIC VARIABILITY IN ALZHEIMER'S DISEASE DERIVED FROM AN FDG-PET BASED UNSUPERVISED MACHINE LEARNING ALGORITHM **2018**, 14, P449-P450		
1	Response to "Letter to the editor concerning "High prevalence of cervical myelopathy in patients with idiopathic normal pressure hydrocephalus" by Naylor et al. (Clinical Neurology and Neurosurgery 2020; 197. /doi:10.1016/j.clineuro.2020.106099. e-pub: 2020 July 17)". *Clinical Neurology and Neurosurgery*, **2021**, 208, 106820	2	